ERBB3 is required for metastasis formation of melanoma cells

Oncogenesis

Volumn 3, Issue , 2014, Pages

  Tiwary, S ^a   Preziosi, M ^a,c   Rothberg, P G ^a   Zeitouni, N ^b,d   Corson, N ^a   Xu, L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; LUNG CARCINOGENESIS; LUNG METASTASIS; LUNG PARENCHYMA; MELANOMA CELL LINE; METASTASIS INHIBITION; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL DESTRUCTION; TUMOR SEEDING; ANIMAL CELL; CANCER PATIENT; CIRCULATING TUMOR CELL; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; MELANOMA METASTASIS; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

EID: 84904811189     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.23     Document Type: Article

References (40)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. New Engl J Med 2004; 351: 998-1012.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011; 364: 2507-2516.
4. Hersey P, Smalley KS, Weeraratna A, Bosenberg M, Zhang XD, Haass NK et al. Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell Melanoma Res 2010; 24: e1-15.
5. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012; 26: 1131-1155.
6. Sullivan RJ, Lorusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 2013; 19: 5283-5291.
7. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
8. Xu L, Hynes RO. GPR56 and TG2: possible roles in suppression of tumor growth by the microenvironment. Cell Cycle 2007; 6: 160-165. (Pubitemid 46232496)
9. Klein CA. Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 2011; 21: 42-49.
10. Mohanty S, Xu L. Experimental metastasis assay. J Vis Exp. 2010; pii: 1942.
11. Kozlowski JM, Hart IR, Fidler IJ, Hanna N. A human melanoma line heterogeneous with respect to metastatic capacity in athymic nude mice. J Natl Cancer Inst 1984; 72: 913-917. (Pubitemid 14131734)
12. Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci USA 2006; 103: 9023-9028. (Pubitemid 43902526)
13. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008; 6: 760-769.
14. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75: 770-787. (Pubitemid 350086174)
15. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15: 2452-2467. (Pubitemid 26151185)
16. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994; 13: 2831-2841.
17. Soltoff SP, Carraway 3rd KL, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994; 14: 3550-3558. (Pubitemid 24160762)
18. Hellyer NJ, Cheng K, Koland JG. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 1998; 333: Pt 3 757-763. (Pubitemid 28398546)
19. Rajkumar T, Stamp GW, Hughes CM, Gullick WJ. c-erbB3 protein expression in ovarian cancer. Clin Mol Pathol 1996; 49: M199-M202. (Pubitemid 26259644)
20. Gyorffy B, Lage H. A Web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol 2007; 127: 394-399. (Pubitemid 46106919)
21. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004; 6: R246-R251.
22. Ueno Y, Sakurai H, Tsunoda S, Choo MK, Matsuo M, Koizumi K et al. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008; 123: 340-347. (Pubitemid 351842018)
23. Zhang K, Wong P, Duan J, Jacobs B, Borden EC, Bedogni B. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival. Pigment Cell Melanoma Res 2013; 26: 408-414.
24. Fattore L, Marra E, Pisanu ME, Noto A, Belleudi F, de Vitis C et al. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med 2013; 11: 180.
25. Belleudi F, Marra E, Mazzetta F, Fattore L, Giovagnoli MR, Mancini R et al. Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Cell Cycle 2012; 11: 1455-1467.
26. Abel EV, Basile KJ, Kugel 3rd CH, Witkiewicz AK, Le K, Amaravadi RK et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest 2013; 123: 2155-2168.
27. Xu L. GPR56 interacts with extracellular matrix and regulates cancer progression. Adv Exp Med Biol 2010; 706: 98-108.
28. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 2010; 107: 14903-14908.
29. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683-695.
30. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009; 21: 177-184.
31. Zhang K, Wong P, Zhang L, Jacobs B, Borden EC, Aster JC et al. A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene 2012; 31: 4609-4618.
32. Liu J, Kern JA. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Respir Cell Mol Biol 2002; 27: 306-313. (Pubitemid 34979288)
33. Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L et al. Rasassociated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res 2006; 66: 7880-7888. (Pubitemid 44299150)
34. Kaufmann WK, Nevis KR, Qu P, Ibrahim JG, Zhou T, Zhou Y et al. Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol 2008; 128: 175-187. (Pubitemid 350249366)
35. Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline-and 4-(phenylamino)pyrido. J Med Chem 2000; 43: 3199.
36. Djerf Severinsson EA, Trinks C, Green H, Abdiu A, Hallbeck AL, Stal O et al. The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochem Biophys Res Commun. 2011; 414: 563-568.
37. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-475.
38. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70: 2485-2494.
39. Buac K, Xu M, Cronin J, Weeraratna AT, Hewitt SM, Pavan WJ. NRG1/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation. Pigment Cell Melanoma Res 2009; 22: 773-784.
40. Gordon-Thomson C, Jones J, Mason RS, Moore GP. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. Melanoma Res 2005; 15: 21-28. (Pubitemid 40354470)